Healthcare / BiotechnologyKOSDAQ
$6970.00
+40.00 (+0.58%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $-2.0B · quality 33.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
27/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$168.2B
P/E
633.6x
↑EV/EBITDA
36.4x
↑ROE
0.9%
↑Gross Margin
63.1%
↑Debt/Equity
0.94
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+14.6%
FCF CAGR
—
FCF margin
-13.4%
FCF / Net income
-7.47x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $15.20B · net income $273.4M · FCF $-2.04B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $15.20B | $15.20B | $12.89B | $12.46B | $10.10B |
| Net Income | $273.4M | $273.4M | $-11.93B | $-1.36B | $-8.09B |
| EBITDA | $5.26B | $5.26B | $-6.89B | $4.56B | $-2.92B |
| EPS | 11.00 | 11.00 | -165.33 | -56.33 | -336.33 |
| Gross Margin | 63.1% | 63.1% | 63.3% | 64.7% | 58.7% |
| Operating Margin | -28.6% | -28.6% | -39.3% | -41.3% | -52.4% |
| Net Margin | 1.8% | 1.8% | -92.6% | -10.9% | -80.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.94 | 0.94 | 0.90 | 0.85 | 0.76 |
| Current Ratio | 15.73 | 15.73 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-2.04B | $-2.04B | $-3.51B | $1.00B | $-6.98B |
| Returns | |||||
| ROE | 0.9% | 0.9% | -38.2% | -3.2% | -18.5% |
| Valuation | |||||
| P/E | 633.64 | 633.64 | — | — | — |
| EV/EBITDA | 36.35 | 36.35 | — | 42.13 | — |
| P/B | 5.41 | 5.41 | 6.30 | 3.84 | 1.99 |
| Growth & Yield | |||||
| Revenue Growth | 17.9% | 17.9% | 3.4% | 23.4% | — |
| EPS Growth | 106.7% | 106.7% | -193.5% | 83.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
283.1%
EPS terminal req.
$618.47
Spread vs growth
-176.4%
5Y implied EPS CAGR
132.6%
EPS terminal req.
$748.35
Spread vs growth
-25.9%
10Y implied EPS CAGR
59.9%
EPS terminal req.
$1205.23
Spread vs growth
46.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-38.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-165.33 → 11.00
Residual
-38.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.